Cato Research Appoints Life Sciences Leader And Innovator To Executive Chairman

Dr. Mark Goldberg Joins Board to Support Company’s Growth and Expansion
DURHAM, NC – April 3, 2019 – Cato Research, LLC (CATO), a global provider of
regulatory and clinical research services, announced today that its board of directors
has appointed Mark Goldberg, M.D. to executive chairman, effective immediately. Dr.
Goldberg brings to CATO more than 25 years of leadership and innovation experience
in building premier life sciences businesses. Read Full Press Release

Lynda Sutton, president and cofounder of Cato BioVentures, a family owned venture capital of Cato Holdings, was recently featured in BioWorld

Lynda Sutton, principle and cofounder of Cato BioVentures, a family owned venture capital of Cato Holdings, was recently featured in BioWorld’s article titled, “Alternative to traditional venture capital money could fill translational gaps” by Jennifer Boggs, for her panel discussion at this year’s January RESI conference featuring Cato BioVentures’ innovative investment approaches in the healthcare sector:

“Cato Bioventures, for instance, started investing in gene therapy in 2000. “We’re finally seeing early results,” said Lynda Sutton, principal and co-founder.

Launched in 1988 as the venture capital affiliate of Cato Holding, a privately held family fund, has built a portfolio of firms, including those developing therapeutics, medical devices and stem cell therapies. It invests in firms at all stages of development and across multiple therapeutic areas, and its funds have gone into both public and private firms. Cato Bioventures offers a two-pronged approach to its investments, said Sutton, who, like de Souza, is another pharma veteran. The first is to look for technology “that needs a home, bring it in and form a company around it,” with the aim of getting it to a value inflection point. The second involves looking for companies with good management, promising technology and invest money and resources to complement drug development efforts.”

http://www.bioworld.com/content/alternative-traditional-venture-capital-money-could-fill-translational-gaps-0

Mallinckrodt plc (NYSE:MNK) today announced it has entered into a licensing agreement for development and commercialization of NeuroproteXeon’s investigational, pharmaceutical-grade xenon gas for inhalation therapy being evaluated to improve survival and functional outcomes for patients resuscitated after a cardiac arrest.

Mallinckrodt plc (NYSE:MNK) today announced it has entered into a licensing agreement for development and commercialization of NeuroproteXeon’s investigational, pharmaceutical-grade xenon gas for inhalation therapy being evaluated to improve survival and functional outcomes for patients resuscitated after a cardiac arrest.